Atomoxetine restores the response inhibition network in Parkinson's disease

Brain

Volumn 139, Issue 8, 2016, Pages 2235-2248

  Rae, Charlotte L ^a,b   Nombela, Cristina ^a   Rodríguez, Patricia Vázquez ^a   Ye, Zheng ^a   Hughes, Laura E ^a,b   Jones, P Simon ^a   Ham, Timothy ^a   Rittman, Timothy ^a   Coyle Gilchrist, Ian ^a   Regenthal, Ralf ^c   Sahakian, Barbara J ^a,d   Barker, Roger A ^a   Robbins, Trevor W ^d,e   Rowe, James B ^a,b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e University of Cambridge   (United Kingdom)

Author keywords

atomoxetine; effective connectivity; Parkinson's disease; response inhibition; stop signal task

Indexed keywords

ATOMOXETINE; LEVODOPA; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

AGED; ARTICLE; BEHAVIOR CHANGE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONNECTOME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FRACTIONAL ANISOTROPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODYNAMICS; HUMAN; IDIOPATHIC DISEASE; INFERIOR FRONTAL GYRUS; MALE; MULTIPLE REGRESSION; NERVE CELL NETWORK; NEUROMODULATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; REGIONAL PERFUSION; RESPONSE INHIBITION NETWORK; SPIN LABELING; SUPPLEMENTARY MOTOR AREA; TASK PERFORMANCE; TREATMENT RESPONSE; WHITE MATTER; BLOOD; COMBINATION DRUG THERAPY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG EFFECTS; EXECUTIVE FUNCTION; INHIBITION (PSYCHOLOGY); MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; SEVERITY OF ILLNESS INDEX;

ADRENERGIC UPTAKE INHIBITORS; AGED; ATOMOXETINE HYDROCHLORIDE; CORPUS STRIATUM; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXECUTIVE FUNCTION; FEMALE; HUMANS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE NET; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PREFRONTAL CORTEX; SEVERITY OF ILLNESS INDEX;

EID: 84982993838     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww138     Document Type: Article

References (85)

1. Agosta F, Kostic VS, Davidovic K, Kresojevic N, Sarro L, Svetel M, et al. White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. Mov Disord 2013; 28: 772-8.
2. Amunts K, Lenzen M, Friederici AD, Schleicher A, Morosan P, Palomero-Gallagher N, et al. Broca's region: novel organizational principles and multiple receptor mapping. PLoS Biol 2010;8: e1000489.
3. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW. Stopsignal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 2003; 6: 115-6.
4. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex: one decade on. Trends Cogn Sci 2014; 18: 177-85.
5. Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, Boulinguez P, et al. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol 2009; 66: 817-24.
6. Bari A, Mar AC, Theobald DE, Elands SA, Oganya KC, Eagle DM, et al. Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci 2011; 31: 9254-63.
7. Bari A, Robbins TW. Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology 2013; 230: 89-111.
8. Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, et al. Atomoxetine enhances connectivity of prefrontal networks in Parkinson's disease. Neuropsychopharmacology 2016; 41: 2171-7.
9. Boudrias MH, Goncalves CS, Penny WD, Park CH, Rossiter HE, Talelli P, et al. Age-related changes in causal interactions between cortical motor regions during hand grip. Neuroimage 2012; 59: 3398-405.
10. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711.
11. Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007; 62: 977-84.
12. Chamberlain SR, Hampshire A, Muller U, Rubia K, Del Campo N, Craig K, et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 2009; 65: 550-5.
13. Chambers CD, Bellgrove MA, Stokes MG, Henderson TR, Garavan H, Robertson IH, et al. Executive brake failure following deactivation of human frontal lobe. J Cogn Neurosci 2006; 18: 444-55.
14. Chumbley JR, Friston KJ. False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage 2009; 44: 62-70.
15. Clemow DB. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med 2014; 126: 196-8.
16. Coxon JP, Van Impe A, Wenderoth N, Swinnen SP. Aging and inhibitory control of action: cortico-subthalamic connection strength predicts stopping performance. J Neurosci 2012; 32: 8401-12.
17. Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, Simmons A, et al. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medicationnaive ADHD boys. Cereb Cortex 2014; 24: 174-85.
18. Cummins TD, Hawi Z, Hocking J, Strudwick M, Hester R, Garavan H, et al. Dopamine transporter genotype predicts behavioural and neural measures of response inhibition. Mol Psychiatry 2012; 17: 1086-92.
19. David O, Guillemain I, Saillet S, Reyt S, Deransart C, Segebarth C, et al. Identifying neural drivers with functional MRI: an electrophysiological validation. PLoS Biol 2008; 6: 2683-97.
20. Duann JR, Ide JS, Luo X, Li CS. Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition. J Neurosci 2009; 29: 10171-9.
21. Eagle DM, Bari A, Robbins TW. The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/ no-go tasks. Psychopharmacology 2008; 199: 439-56.
22. Eagle DM, Baunez C. Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition. Neurosci Biobehav Rev 2010; 34: 50-72.
23. Forstmann BU, Keuken MC, Jahfari S, Bazin PL, Neumann J, Schafer A, et al. Cortico-subthalamic white matter tract strength predicts interindividual efficacy in stopping a motor response. Neuroimage 2012; 60: 370-5.
24. Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318: 1309-12.
25. Friston K, Moran R, Seth AK. Analysing connectivity with Granger causality and dynamic causal modelling. Curr Opin Neurobiol 2013; 23: 172-8.
26. Friston KJ, Harrison L, Penny W. Dynamic causal modelling. Neuroimage 2003; 19: 1273-302.
27. Gilbert JR, Symmonds M, Hanna MG, Dolan RJ, Friston KJ, Moran RJ. Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: case studies of single gene mutations. Neuroimage 2016; 124(Pt A): 43-53.
28. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev 2013; 9: 13-24.
29. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC. Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 2011; 18: 703-10.
30. Goulden N, McKie S, Thomas EJ, Downey D, Juhasz G, Williams SR, et al. Reversed frontotemporal connectivity during emotional face processing in remitted depression. Biol Psychiatry 2012; 72: 604-11.
31. Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB, Lokkegaard A, et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol 2014; 75: 829-36.
32. Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB, Lokkegaard A, et al. Abnormal dopaminergic modulation of striatocortical networks underlies levodopa-induced dyskinesias in humans. Brain 2015; 138(Pt 6): 1658-66.
33. Hughes LE, Barker RA, Owen AM, Rowe JB. Parkinson's disease and healthy aging: independent and interacting effects on action selection. Hum Brain Mapp 2010; 31: 1886-99.
34. Hughes LE, Altena E, Barker RA, Rowe JB. Perseveration and choice in Parkinson's disease: the impact of progressive frontostriatal dysfunction on action decisions. Cereb Cortex 2013; 23: 1572-81.
35. Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson's disease. Parkinson's Dis 2015; 2015: 609428.
36. Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging 2007; 25: 978-88.
37. Kahan J, Urner M, Moran R, Flandin G, Marreiros A, Mancini L, et al. Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity. Brain 2014; 137(Pt 4): 1130-44.
38. Kass RE, Raftery AE. Bayes factors. J Ame Stati Assoc 1995; 90: 773-95.
39. Kehagia AA, Housden CR, Regenthal R, Barker RA, Muller U, Rowe J, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 2014; 137(Pt 7): 1986-97.
40. Logan GD, Cowan WB. On the ability to inhibit thought and action: a theory of an act of control. Psychol Rev 1984; 91: 295-327.
41. Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, Zabroski J, et al. Imaging the norepinephrine transporter in humans with (S, S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol 2007; 34: 667-79.
42. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277-82.
43. Michely J, Volz LJ, Barbe MT, Hoffstaedter F, Viswanathan S, Timmermann L, et al. Dopaminergic modulation of motor network dynamics in Parkinson's disease. Brain 2015; 138: 664-78.
44. Mirabella G, Iaconelli S, Romanelli P, Modugno N, Lena F, Manfredi M, et al. Deep brain stimulation of subthalamic nuclei affects arm response inhibition in Parkinson's patients. Cereb Cortex 2012; 22: 1124-32.
45. Moppett IK, Sherman RW, Wild MJ, Latter JA, Mahajan RP. Effects of norepinephrine and glyceryl trinitrate on cerebral haemodynamics: transcranial Doppler study in healthy volunteers. Br J Anaesth 2008; 100: 240-4.
46. Moran RJ, Campo P, Symmonds M, Stephan KE, Dolan RJ, Friston KJ. Free energy, precision and learning: the role of cholinergic neuromodulation. J Neurosci 2013; 33: 8227-36.
47. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 2002; 43: 111-7.
48. Nandam LS, Hester R, Wagner J, Dean AJ, Messer C, Honeysett A, et al. Dopamine D(2) receptor modulation of human response inhibition and error awareness. J Cogn Neurosci 2013; 25: 649-56.
49. Napier TC, Corvol JC, Grace AA, Roitman JD, Rowe J, Voon V, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord 2014; 30: 141-9.
50. Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of impulsivity in Parkinson's disease. PloS One 2014a; 9: e85747.
51. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 2014b; 137(Pt 10): 2743-58.
52. Obeso I, Wilkinson L, Casabona E, Bringas ML, Alvarez M, Alvarez L, et al. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res 2011a; 212: 371-84.
53. Obeso I, Wilkinson L, Jahanshahi M. Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. Exp Brain Res 2011b; 213: 435-45.
54. Penny WD, Stephan KE, Daunizeau J, Rosa MJ, Friston KJ, Schofield TM, et al. Comparing families of dynamic causal models. PLoS Comput Biol 2010; 6: e1000709.
55. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB. White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function. Neuroimage 2012; 62: 1675-84.
56. Rae CL, Hughes LE, Weaver C, Anderson MC, Rowe JB. Selection and stopping in voluntary action: a meta-analysis and combined fMRI study. Neuroimage 2014; 86: 381-91.
57. Rae CL, Hughes LE, Anderson MC, Rowe JB. The prefrontal cortex achieves inhibitory control by facilitating subcortical motor pathway connectivity. J Neurosci 2015; 35: 786-94.
58. Ray NJ, Brittain JS, Holland P, Joundi RA, Stein JF, Aziz TZ, et al. The role of the subthalamic nucleus in response inhibition: evidence from local field potential recordings in the human subthalamic nucleus. Neuroimage 2012; 60: 271-8.
59. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010; 11: 760-72.
60. Rigoux L, Stephan KE, Friston KJ, Daunizeau J. Bayesian model selection for group studies-revisited. Neuroimage 2014; 84: 971-85.
61. Rowe JB. Connectivity analysis is essential to understand neurological disorders. Fron Syst Neurosci 2010; 4: 144.
62. Rowe JB, Hughes LE, Barker RA, Owen AM. Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage 2010; 52: 1015-26.
63. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44: 571-90.
64. Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al. The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol 2014; 14: 204.
65. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006; 31: 1487-505.
66. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009; 44: 83-98.
67. Song C, Schwarzkopf DS, Lutti A, Li B, Kanai R, Rees G. Effective connectivity within human primary visual cortex predicts interindividual diversity in illusory perception. J Neurosci 2013; 33: 18781-91.
68. Stephan KE, Kasper L, Harrison LM, Daunizeau J, den Ouden HE, Breakspear M, et al. Nonlinear dynamic causal models for fMRI. Neuroimage 2008; 42: 649-62.
69. Stephan KE, Penny WD, Daunizeau J, Moran RJ, Friston KJ. Bayesian model selection for group studies. Neuroimage 2009a; 46: 1004-17.
70. Stephan KE, Tittgemeyer M, Knosche TR, Moran RJ, Friston KJ. Tractography-based priors for dynamic causal models. Neuroimage 2009b; 47: 1628-38.
71. Stephan KE, Penny WD, Moran RJ, den Ouden HE, Daunizeau J, Friston KJ. Ten simple rules for dynamic causal modeling. Neuroimage 2010; 49: 3099-109.
72. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
73. van der Schaaf ME, Zwiers MP, van Schouwenburg MR, Geurts DE, Schellekens AF, Buitelaar JK, et al. Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala. Front Neurosci 2013; 7: 142.
74. van Schouwenburg MR, Zwiers MP, van der Schaaf ME, Geurts DE, Schellekens AF, Buitelaar JK, et al. Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function. Psychopharmacology 2013; 227: 521-31.
75. Vazey EM, Aston-Jones G. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci 2012; 6: 48.
76. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140-9.
77. Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C. Noradrenergic enhancement improves motor network connectivity in stroke patients. Ann Neurol 2011; 69: 375-88.
78. Wheeler-Kingshott C, Cercignani M. About axial and radial diffusivities. Magn Res Med 2009; 61: 1255-60.
79. Whelan R, Conrod PJ, Poline JB, Lourdusamy A, Banaschewski T, Barker GJ, et al. Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci 2012; 15: 920-5.
80. Wiecki TV, Frank MJ. A computational model of inhibitory control in frontal cortex and basal ganglia. Psychol Rev 2013; 120: 329-55.
81. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998; 71: 274-80.
82. Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014; 82: 308-16.
83. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014; 137(Pt 4): 1145-55.
84. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Improving response inhibition in Parkinson's disease with atomoxetine. Biol Psychiatry 2015; 77: 740-8.
85. Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, et al. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp 2016; 37: 1026-37.